Eduardo Bravo (file photo)

Ed­uar­do Bra­vo re­turns to bring Eu­ro­pean biotech in on the SPAC splurge

The last year’s SPAC boom has been dom­i­nat­ed so far by US-based VCs. Now a promi­nent Eu­ro­pean biotech ex­ec­u­tive and a cou­ple in­vestors are get­ting in on the game.

Ed­uar­do Bra­vo, the Big Phar­ma alum and for­mer CEO of the cell ther­a­py com­pa­ny TiGenix, has launched Eu­ro­pean Biotech Ac­qui­si­tion. Based in Am­s­ter­dam (if a SPAC can be said to be based any­where be­sides the Cay­man Is­lands and Ama­zon Web Ser­vices), the new shell com­pa­ny will try to raise $100 mil­lion and use it to take a Eu­ro­pean biotech pub­lic with­in 2 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.